Wilkinson 2006.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 182, ovarian cancer (stage I‐IV); concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = if body weight > 45 kg 10000 IU sc TIW, if < 45 kg 5000 IU sc TIW hb‐target = 12‐14 g/dL planned ESA duration = during chemotherapy
Outcomes	Primary: Hb response; secondary: QoL, transfusion, tumor response
Notes	study number = 75688
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	a prospective randomization procedure will be employed
Allocation concealment?	Unclear risk	assigned envelopes, sealed, but it is unclear whether they were opaque and sequentially numbered